Comparison of Evidence-Based Versus Non–Evidence-Based Pharmacotherapy on the Risk of Cardiovascular Hospitalization and All-Cause Mortality Among Patients With Established Cardiovascular Disease
To access this article, please choose from the options below
This study was funded by GlaxoSmithKline, King of Prussia, Pennsylvania. Dr. Nichols has received research support from Amgen, Incorporated (Thousand Oaks, California), Novo Nordisk (Bagsvaerd, Denmark), Novartis Pharmaceuticals (Basel, Switzerland), Tethys BioScience, Incorporated (Emeryville, California), and Merck & Company, Incorporated (Whitehouse Station, New Jersey).
Dr. Wang is a GlaxoSmithKline employee.
By contract and in accordance with the Uniform Requirements for Biomedical Journal submissions, Dr. Nichols had the final say in the design, interpretation, and presentation of the data and text.
PII: S0002-9149(09)02677-0
doi:10.1016/j.amjcard.2009.11.008
© 2010 Elsevier Inc. All rights reserved.
